India Glycols · NSE: INDIAGLYCO · BSE: 500201

Q3 FY24 results · Oct–Dec 2023

India Glycols reported revenue from operations of ₹2,118.94 crore (up 39.0% from Q3 FY23) and net profit of ₹41.63 crore (down 16.8% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.

Consolidated · ₹ crore
ItemQ3 FY24Q3 FY23YoYQ2 FY24QoQ
Revenue from operations2,118.941,524.42+39.0%1,869.88+13.3%
Other income4.556.99−34.9%10.73−57.6%
Total income2,123.491,531.41+38.7%1,880.61+12.9%
Profit before share of associates & JVs and tax49.1655.61−11.6%49.23−0.1%
Share of profit/(loss) of associates & JVs4.73(2.35)0.87
Net profit for the period41.6350.03−16.8%38.01+9.5%
EPS, basic (₹)13.4516.16−16.8%12.27+9.6%
Net margin (%)2.03.32.0

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ3 FY24Q3 FY23YoYQ2 FY24QoQ
Revenue from operations2,119.191,524.17+39.0%1,870.64+13.3%
Other income4.558.31−45.2%10.73−57.6%
Total income2,123.741,532.48+38.6%1,881.37+12.9%
Profit before tax50.0516.58+201.9%47.76+4.8%
Net profit for the period37.7913.35+183.1%35.67+5.9%
EPS, basic (₹)12.214.31+183.3%11.52+6.0%
Net margin (%)1.80.91.9
Consolidated
Filed with BSE
19 Feb 2024, 14:35 IST
Board meeting
02 Feb 2024
Period
01 Oct 2023 to 31 Dec 2023
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
19 Feb 2024, 14:35 IST
Board meeting
02 Feb 2024
Period
01 Oct 2023 to 31 Dec 2023
Review status
Unaudited
Source
XBRL filing on BSE